Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Tyrosine kinase inhibitor of FLT3, AXL, and ALK | Tyrosine kinase inhibitor of FLT3, AXL, and ALK | ||
+ | |||
+ | ==Preliminary data== | ||
+ | ===[[Acute myeloid leukemia]]=== | ||
+ | # Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Jun 20. [Epub ahead of print] [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30416-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28645776 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] |
Revision as of 02:41, 30 July 2017
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Preliminary data
Acute myeloid leukemia
- Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Jun 20. [Epub ahead of print] link to original article PubMed